Veru (NASDAQ:VERU – Get Free Report) is anticipated to release its Q3 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Veru to post earnings of ($0.06) per share for the quarter.
Veru (NASDAQ:VERU – Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts expect Veru to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Veru Price Performance
Shares of VERU stock opened at $0.37 on Thursday. The company has a market cap of $53.57 million, a PE ratio of -1.52 and a beta of -0.72. The stock’s 50 day simple moving average is $0.58 and its two-hundred day simple moving average is $0.57. Veru has a 1 year low of $0.36 and a 1 year high of $1.42.
About Veru
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Recommended Stories
- Five stocks we like better than Veru
- Investing In Preferred Stock vs. Common Stock
- RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum?
- Which Wall Street Analysts are the Most Accurate?
- How DigitalOcean’s Focus Is Fueling Explosive Growth
- EV Stocks and How to Profit from Them
- Can Celsius Stock Keep Its Momentum Going Any Longer?
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.